Thromb Haemost 1999; 82(S 01): 85-91
DOI: 10.1055/s-0037-1615561
Commentaries
Schattauer GmbH

Treatment of Ischaemic Stroke

F. Masuhr
1   From the Department of Neurology, Charité Medical School, Humboldt University, Berlin, Germany
,
K. Einhäupl
1   From the Department of Neurology, Charité Medical School, Humboldt University, Berlin, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
14 December 2017 (online)

Summary

Stroke is a neurological emergency that requires rapid diagnostic workup and immediate treatment. Basic medical management such as maintenance of a high level of systemic blood pressure, provision of an optimal supply of oxygen, and correction of hyperthermia, hyperglycaemia and hypovolemia can contribute to a more favourable clinical outcome of stroke patients. Neuroprotective drugs have shown to be effective in reducing cerebral infarct size in several animal species but their clinical benefit in stroke patients remains to be proven. Neither heparin nor aspirin can improve neurological outcome or significantly reduce death or dependency several months after the ischaemic event, but aspirin is clearly effective in reducing early death or stroke recurrence within the first few weeks. Early anticoagulation should be used for patients at high risk for recurrent cardioembolic stroke and with carotid or vertebral artery dissection, although this recommendation is not based on the results of randomised controlled trials.

 
  • References

  • 1 Astrup J, Siesjo B, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981; 12 (6) 723-5.
  • 2 Ginsberg MD, Pulsinelli WA. The ischemic penumbra injury tresholds and the therapeutic window for acute stroke. Ann Neurol 1994; 36: 553-4.
  • 3 Paschen W, Hossmann KA. Neuroprotection in cerebral ischemia. In: Cerebral protection in cerebrovascular and aortic surgery. Ennker J, Coselli JS, Treasure T. eds. Darmstadt: Steinkopff Verlag 1997: 3-10.
  • 4 Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wien-hard K. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992; 12: 193-203.
  • 5 Marchal G, Beaudouin V, Rioux P, de la Sayette V, Le Doze F, Viader F, Derlon JM, Baron JC. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke. A correlative PET-CT study with voxel-based data analysis. Stroke 1996; 27: 599-606.
  • 6 Baired AE, Benfield A, Schlaug G, Siewert B, Lovblad KO, Edelman RR, Warach S. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol 1997; 41: 581-9.
  • 7 Indredavik B, Bakke F, Solberg R, Rokseth R, Haaheim L, Holme I. Benefit of a stroke unit: a randomised controlled trial. Stroke 1991; 22: 1026-31.
  • 8 Jorgensen HS, Nakamaya H, Raaschou HO, Larsen K, Hubbe P, Olsen TS. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost. A community-based study. Stroke 1995; 26: 1178-82.
  • 9 Dirnagl U, Pulsinelli W. Autoregulation of cerebral blood flow in experimental focal brain ischemia. J Cereb Blood Flow Metab 1990; 10: 327-36.
  • 10 Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Effect of blood pressure and diabetes on stroke in progression. Lancet 1994; 344: 156-9.
  • 11 Wahlgren NG, MacMahon DG, de Keyser J, Indredavik B, Ryman H. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994; 4: 204-10.
  • 12 Dirnagl U. Cerebral ischemia: the microcirculation as trigger and target. In: Progress in Brain Research, Vol. 96. Kogure K, Hosmann KA, Siesjo BK. eds. Amsterdamm: Elsevier Science Publishers 1993: 49-65.
  • 13 Courten-Meyers G, Myers RE, Schoolfield L. Hyperglycaemia enlarges infarct size in cerebrovascular occlusion in cats. Stroke 1988; 19: 623-30.
  • 14 Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F. Increased damage after ischemic stroke in patients with hyperglycaemia with or without established diabetes mellitus. Am J Med 1983; 74: 540-4.
  • 15 Weir CJ, Murray AG, Dyker AG. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997; 314: 1303-6.
  • 16 Hacke W, Hennerici M, Gelmers HJ, Kramer G. Pathophysiology of cerebral ischemia. In: Cerebral Ischemia. Hacke W, Hennerici M, Gelmers HJ, Kramer G. eds. Berlin, Heidelberg, New York London, Paris, Tokyo, Hong Kong Barcelona: Springer-Verlag 1991: 17-30.
  • 17 Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, Olsen TS. Body temperature in acute stroke: relation to stroke severity, infarct size mortality, and outcome. Lancet 1996; 347: 422-5.
  • 18 Griepp E, Griepp R. Cerebral consequences of hypothermic circulatory arrest in adults. J Cardiac Surg 1992; 7 (2) 134-55.
  • 19 Chyatte D, Elefteriades J, Kim B. Profound hypothermia and circulatory arrest for aneurysm surgery. J Neurosurg 1989; 70: 489-91.
  • 20 Maher J, Hachinski V. Hypothermia as a potential treatment for cerebral ischemia. Cerebrovasc Brain Metabol Rev 1993; 5: 277-300.
  • 21 Schwab S, Spranger M, Aschoff A, Steiner T, Hacke W. Brain temperature monitoring and modulation in patients with severe MCA infarction. Neurology 1997; 48: 762-7.
  • 22 Heros RC. Surgical treatment of cerebellar infarction. Stroke 1992; 23 (7) 937-8.
  • 23 Hornig CR, Rust DS, Busse O, Jauss M, Laun A. Space-occupying cerebellar infarction. Clinical course and treatment. Stroke 1994; 25 (2) 372-4.
  • 24 Dirnagl U, Iadecola C, Moskowitz A. Pathobiology of ischaemic stroke: an integrated view. TINS. 1999 in press.
  • 25 Prass K, Dirnagl U. Glutamate antagonists in therapy of stroke. Rest Neurol Neurosci 1998; 13: 3-10.
  • 26 Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26: 503-13.
  • 27 Dugan LL, Choi DW. Excitotoxicity, free radicals and cell membrane changes. Ann Neurol 1994; 35: 17-21.
  • 28 Choi DW. Excitotoxic cell death. J Neurobiol 1992; 23: 1261-76.
  • 29 Back T, Kohno K, Hossmann KA. Cortical negative DC deflections following middle cerebral artery occlusion and KCl-induced spreading depression: effect on blood flow, tissue oxygenation and electroencephalogram. J Cereb Blood Flow Metabol 1994; 14: 12-9.
  • 30 Mies G, Iijima T, Hossmann KA. Correlation between peri-infarct DC shifts and ischemic neuronal damage in cerebral cortex of rat. Neuroreport 1993; 4: 709-11.
  • 31 Iijima T, Mies G, Hossmann KA. Repeated negative DC deflections in rat cortex following middle cerebral artery occlusion are abolished by MK-801: effect on volume of ischemic injury. J Cereb Blood Flow Metab 1992; 12: 727-33.
  • 32 Hossmann KA. Periinfarct depolarizations. Cerebrovasc Brain Metabol Rev 1996; 8: 195-208.
  • 33 Turski L, Huth A, Sherdown M, McDonald F, Neuhaus R, Schneider HH, Dirnagl U, Wiegand F, Jacobsen P, Ottow E. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci USA 1998; 95: 10960-5.
  • 34 Davis SM, Albers GW, Diener HC, Lees KR, Norris J. Termination of Acute Stroke Studies Involving Selfotel Treatment. ASSIST Steering Comittee. Lancet. 1997 349. 32.
  • 35 Grotta J. for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Stroke 1997; 28: 2338-46.
  • 36 Diener HC. for the European and Australian Lubeluzole Ischaemic Stroke Study Group. Cerebrovasc Dis 1998; 8: 172-81.
  • 37 Major ongoing stroke trials. Stroke 1999; 30: 487-91.
  • 38 The RANTTAS Investigators. A randomised trial of tirilazad mesylate in patients with acute stroke. Stroke 1996; 27: 76-81.
  • 39 Mohr JP, Orgogozo JM, Harrison MJG, Hennerici M, Wahlgren NG, Gelmers JH, Martinez-Vila E, Dycka J, Tettenborn D. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994; 4: 197-203.
  • 40 Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997; 49: 66-9.
  • 41 Becker KJ. Inflammation and acute stroke. Curr Opin Neurol 1998; 11: 45-9.
  • 42 Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol 1996; 6: 667-72.
  • 43 Liu PK, Salminen A, He YY. Suppression of ischaemia-induced Fos expression and AP-1 activity by an antisense oligonucleotide to c-fos mRNA. Ann Neurol 1994; 36: 566-76.
  • 44 Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gomez-Isla T, Hyman BT, Moskowitz MA. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 1998; 18: 238-47.
  • 45 Kay R, Wong KS, YU YL, Chan YW, Tsoi TH, Akuja AT, Chan FL, Fong KY, Law CB, Wong A, Woo J. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588-93.
  • 46 Hommel M. for the FISS bis Investigators Group. Fraxiparine in ischaemic stroke study (FISS bis). Cerebrovasc Dis. 1998 8. 63.
  • 47 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin both, or neither among 19435 patients with acute ischemic stroke. Lancet 1997; 349: 1569-81.
  • 48 Sandercock PAG, van den Belt AGM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25.
  • 49 Chamorro A, Vila N, Saiz A, Alday M, Tolosa E. Early anticoagulation after large cerebral embolic infarction: a safety study. Neurology 1995; 45: 861-5.
  • 50 Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998; 114: 683-98.
  • 51 EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
  • 52 Cerebral Embolism, Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983; 14: 668-76.
  • 53 Sturzenegger M. Spontaneous internal carotid artery dissection: early diagnosis and management in 44 patients. J Neurol 1995; 242 (4) 231-8.
  • 54 Miller VT, Hart RG. Heparin anticoagulation in acute brain ischemia. Stroke 1988; 19: 403-6.
  • 55 Einhaupl KM, Villringer A, Meister W, Mehraein S, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P. Heparin treatment of cerebral sinus venous thrombosis. Lancet 1991; 333: 597-600.
  • 56 CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischemic stroke. Lancet 1997; 349: 1641-9.
  • 57 Bousser MG. Aspirin or heparin immediately after a stroke?. Lancet 1997; 349: 1564-5.
  • 58 Masuhr F, Busch M, Einhaupl KM. Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe. Stroke 1998; 29: 339-45.